How have TTNP shares performed in 2024?

Titan Pharmaceuticals' stock was trading at $8.25 at the beginning of 2024. Since then, TTNP shares have decreased by 12.0% and is now trading at $7.2572. View the best growth stocks for 2024 here .

Are investors shorting Titan Pharmaceuticals?

Titan Pharmaceuticals saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 3,900 shares, a decline of 67.5% from the March 15th total of 12,000 shares. Based on an average daily volume of 12,500 shares, the short-interest ratio is currently 0.3 days. Currently, 0.6% of the company's stock are short sold. View Titan Pharmaceuticals' Short Interest .

When is Titan Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our TTNP earnings forecast .

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced its quarterly earnings results on Tuesday, March, 30th. The specialty pharmaceutical company reported ($17.20) EPS for the quarter, beating the consensus estimate of ($26.60) by $9.40. Titan Pharmaceuticals had a negative net margin of 2,014.71% and a negative trailing twelve-month return on equity of 165.90%.

When did Titan Pharmaceuticals' stock split?

Shares of Titan Pharmaceuticals reverse split on Tuesday, January 9th 2024. The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Titan Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Bionano Genomics (BNGO) , Gran Tierra Energy (GTE) , Matinas BioPharma (MTNB) , Organigram (OGI) , Zosano Pharma (ZSAN) , Novan (NOVN) , ADMA Biologics (ADMA) , Aeterna Zentaris (AEZS) , CNBX Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI) .

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TTNP

Titan Pharmaceuticals (TTNP) Stock Price, News & Analysis

→ Biden out June 13; Kamala won’t replace him? (From Paradigm Press) (Ad)

Free TTNP Stock Alerts

$7.26

0.00 (0.00%)

(As of 04/16/2024 ET)

Compare

Today's Range: $7.26
▼
$7.26
50-Day Range: $6.27
▼
$9.41
52-Week Range: $5.00
▼
$16.60

Volume: 291 shs
Average Volume: 12,470 shs
Market Capitalization: $6.60 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Titan Pharmaceuticals alerts:

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Titan Pharmaceuticals Stock (NASDAQ:TTNP)

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

TTNP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TTNP Stock News Headlines

April 15, 2024 | americanbankingnews.com

Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com

April 13, 2024 | americanbankingnews.com

Lexeo Therapeutics (NASDAQ:LXEO) and Titan Pharmaceuticals (NASDAQ:TTNP) Critical Contrast

April 16, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

April 7, 2024 | americanbankingnews.com

Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated at StockNews.com

March 2, 2024 | uk.investing.com

Titan Pharmaceuticals Inc (TTNP)

February 20, 2024 | au.finance.yahoo.com

Titan Pharmaceuticals, Inc. (TN70.F)

February 3, 2024 | morningstar.com

Titan Pharmaceuticals Inc TTNP

January 26, 2024 | finanznachrichten.de

Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria

April 16, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

January 25, 2024 | finance.yahoo.com

Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria

January 10, 2024 | benzinga.com

Titan Pharma Stock (NASDAQ:TTNP) Dividends: History, Yield and Dates

December 29, 2023 | finanznachrichten.de

Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Announces Reverse Stock Split and Ratio

December 28, 2023 | washingtonpost.com

Barbie, the Titan submersible and everything else we Googled in 2023

December 28, 2023 | finance.yahoo.com

Titan Pharmaceuticals Announces Reverse Stock Split and Ratio

October 16, 2023 | finance.yahoo.com

Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

September 18, 2023 | seekingalpha.com

Titan Pharmaceuticals reports $9.5M private placement of convertible preferred stock

September 18, 2023 | finance.yahoo.com

Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock

August 28, 2023 | finance.yahoo.com

Unveiling Titan Pharmaceuticals (TTNP)'s Value: Is It Really Priced Right? A Comprehensive Guide

August 13, 2023 | thestreet.com

Titan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment Approval

July 27, 2023 | finance.yahoo.com

Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets

June 29, 2023 | usatoday.com

Patents, lawsuits, safety concerns — then tragedy. A timeline of OceanGate's Titan sub.

May 26, 2023 | finance.yahoo.com

TTNP - Titan Pharmaceuticals, Inc.

May 23, 2023 | sports.yahoo.com

Watch: Prowling tiger bows to ‘titan herd’ of elephants

March 22, 2023 | seekingalpha.com

TTNP Titan Pharmaceuticals, Inc.

December 15, 2022 | finance.yahoo.com

Titan Pharmaceuticals Provides Shareholder Update

December 12, 2022 | nz.finance.yahoo.com

Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.

November 21, 2022 | bizjournals.com

Chapel Hill surgical tech company shapes plan to keep Nasdaq listing

See More Headlines

Receive TTNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/30/2021
Today: 4/16/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:TTNP
CUSIP: N/A
CIK: 910267
Web: www.titanpharm.com
Phone: (650) 244-4990
Fax: 650-244-4956
Employees: 4
Year Founded: 1992

Profitability

EPS (Most Recent Fiscal Year): ($8.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-5,570,000.00
Net Margins: -2,014.71%
Pretax Margin: -3,026.63%
Return on Equity: -165.90%
Return on Assets: -105.75%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.55
Quick Ratio: 5.55

Sales & Book Value

Annual Sales: $180,000.00
Price / Sales: 36.69
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.82 per share
Price / Book: 0.82

Miscellaneous

Outstanding Shares: 910,000
Free Float: 686,000
Market Cap: $6.60 million
Optionable: Optionable
Beta: 1.33

Social Links

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. David Elliot Lazar (Age 33)
CEO & Principal Financial Officer
Comp: $726.08k
Dr. Katherine L. Beebe-DeVarney Ph.D. (Age 63)
President, COO & Director
Comp: $308k
Mr. Mike Fritz
National Sales Director
Jennifer Kiernan
Executive Assistant to CEO & Investor Communications Coordinator
Joe Schrei
Executive Director of Commercial Operations

Key Competitors

View All Competitors

Insiders

David E. Lazar
Sold 169,445 shares
Total: $4.17 M ($24.60/share)

View All Insider Transactions

TTNP Stock Analysis - Frequently Asked Questions

How have TTNP shares performed in 2024?: Titan Pharmaceuticals' stock was trading at $8.25 at the beginning of 2024. Since then, TTNP shares have decreased by 12.0% and is now trading at $7.2572.
View the best growth stocks for 2024 here.
Are investors shorting Titan Pharmaceuticals?: Titan Pharmaceuticals saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 3,900 shares, a decline of 67.5% from the March 15th total of 12,000 shares. Based on an average daily volume of 12,500 shares, the short-interest ratio is currently 0.3 days. Currently, 0.6% of the company's stock are short sold.
View Titan Pharmaceuticals' Short Interest.
When is Titan Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our TTNP earnings forecast.
How were Titan Pharmaceuticals' earnings last quarter?: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced its quarterly earnings results on Tuesday, March, 30th. The specialty pharmaceutical company reported ($17.20) EPS for the quarter, beating the consensus estimate of ($26.60) by $9.40. Titan Pharmaceuticals had a negative net margin of 2,014.71% and a negative trailing twelve-month return on equity of 165.90%.

When did Titan Pharmaceuticals' stock split?: Shares of Titan Pharmaceuticals reverse split on Tuesday, January 9th 2024. The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Titan Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI).
How do I buy shares of Titan Pharmaceuticals?: Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TTNP) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial